Abhimanyu Ojha appointed Chief Financial Officer and Key Managerial Personnel w.e.f. 12 October 2026

Board approved Mr. Abhimanyu Ojha as Chief Financial Officer and Key Managerial Personnel w.e.f. 12 October 2026.

Fri 9 Oct 2026

Effective Date

12 October 2026

Board Meeting Date

Friday, 9 October 2026

Authorised KMP

Mr. Umang Vohra (Chairman & Group CEO), Mr. Abhimanyu Ojha (CFO), Mr. Sisir K Mishra (Company Secretary & Compliance Officer)

The company has a new finance chief.

What was approved

• The Board of Cohance Lifesciences Limited, at its meeting held on Friday, 9 October 2026, approved the appointment of Mr. Abhimanyu Ojha as Chief Financial Officer and Key Managerial Personnel of the Company with effect from 12 October 2026.
• The appointment was made on the recommendation of the Nomination and Remuneration Committee.
• The term of appointment is stated as Not Applicable.

Who is the incoming CFO

• Mr. Ojha has over two decades of experience leading finance functions across multinational healthcare and pharmaceutical companies.
• He served as Global CFO & President Finance at Intas Pharmaceuticals, where he led global finance teams spanning business operations, manufacturing, R&D, accounting, treasury, audit, taxation, corporate finance and FP&A.
• Earlier, he held senior leadership positions at Viatris (formerly Mylan), Sun Pharmaceuticals and Ranbaxy Laboratories.
• The disclosure lists his expertise as covering financial strategy, business partnering, corporate governance, mergers and acquisitions, treasury, tax, risk management and operational excellence.

The second item approved

• A change in the authorised Key Managerial Personnel for the purpose of determining materiality of an event or information and making disclosures to the stock exchanges.
• The authorised KMP are now Mr. Umang Vohra (Chairman & Group CEO), Mr. Abhimanyu Ojha (Chief Financial Officer) and Mr. Sisir K Mishra (Company Secretary & Compliance Officer).
• The Policy for Determining Material Event or Information is also amended to reflect the change, effective from 12 October 2026.

How to read it

• The Chief Financial Officer sits at the centre of a company's accounts, capital decisions and disclosure process, so a change in this seat is a management development investors generally track.
• Mr. Ojha's appointment takes effect on 12 October 2026, and the same date is set for the amended policy.
• The second item is a procedural change: it decides who within the company is authorised to judge whether an event or information is material enough to be disclosed to the exchanges, and that authorised list now includes the new CFO.
• The update gives the incoming CFO's professional background and the effective date of the change.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.